Avadel Pharmaceuticals plc (NasdaqGM:AVDL) is actively evaluating a number of commercial stage products and or companies to acquire, and to divest or out license two of its four platform technologies, Trigger Lock and Medusa„¢. "For a Company of our size and resources, we are narrowing our focus to our two most developed platforms, Micropump® and LiquiTime®. We are pursuing the divestiture or out licensing of Trigger Lock„¢ for abuse deterrence, and Medusa„¢ for extended-release subcutaneous injection. We believe both platforms are robust and well protected from an IP standpoint; however, their development and approval would require substantial investments in clinical work and infrastructure, which we are not currently prepared to support," said Michael Anderson, Chief Executive Officer of Avadel.